Dihydrospiro[dibenzo[a,d][7]annulene-5,4′-imidazol] compounds for the inhibition of beta-secretase

A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula 1

• wherein
• X is CH2;
• Y is CH2;
• R1 and R2 are each independently H, or an optionally substituted alkyl group;
• R3 is H or an alkyl group optionally substituted;
• R4 and R5 are each independently H, halogen, OR11 or an alkyl, alkenyl, or alkynyl, group optionally substituted;
• R6 and R7 are each independently H, halogen, CN, OR25, NR26R27 or an alkyl, alkenyl, alkynyl cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
• each R11 is independently H or an alkyl, haloalkyl, alkenyl or alkynyl group each optionally substituted;
• R12, R13, and R25 are each independently H or an alkyl, haloalkyl, alkenyl, alkynyl cycloalkyl or aryl group each optionally substituted;
• R26 and R27 are each independently H, OR11, COR12, CO2R13 or an alkyl, alkenyl, alkynyl cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted or R26 and R27 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally interrupted by an additional heteroatom selected from O, N or S;
• or
• a tautomer thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof.